Endo Health Solutions, Inc.

MALVERN, Pa., Dec. 2, 2024 /PRNewswire/ -- Endo, Inc. (OTCQX: NDOI) announced today the launch of its ADRENALIN® (epinephrine in 0.9% sodium chloride injection) ready-to-use premixed bag, the first and only FDA-approved, manufacturer-prepared epinephrine premixed intravenous (IV) bag. "The first-ever ready-to-use epinephrine premixed bag represents an advancement for both providers and patients thanks to a delivery system that provides greater workflow efficiency, saves time, and reduces the risk of medication error," said Scott Sims, Senior Vice President and General Manager, Endo Injectable Solutions & Generics. "We are proud to provide critical care products like ADRENALIN® bags—ready when and where our customers need them—through our TruDelivery® portfolio." The ADRENALIN® premixed bag is the latest addition to Endo Injectable Solutions' TruDelivery® product line and platform. Ready-to-use products streamline operations for hospitals by eliminating the need to prepare or transfer the product before patient administration. This may reduce waste and costs, optimize convenience and workflow, and reduce the chance for preparation error—all of which support quality patient care. The ADRENALIN® premixed bag does not require compounding, diluting, mixing, or transferring, which may reduce waste. The single-port IV tubing reduces risk of inadvertently adding other medications to bag. The product also has a 24-month shelf life at room temperature. Endo also offers ADRENALIN® (epinephrine injection, USP) in 1 mL single-dose vials and 30 mL multi-dose vials. ADRENALIN® is used in the treatment of hypotension associated with septic shock. IMPORTANT SAFETY INFORMATION WARNINGS AND PRECAUTIONS Hypertension: Because individual response to epinephrine may vary significantly, monitor blood pressure frequently and titrate to avoid excessive increases in blood pressure. Patients receiving monoamine oxidase inhibitors (MAOI) or antidepressants of the triptyline or imipramine types may experience severe, prolonged hypertension when given epinephrine. Pulmonary Edema: Epinephrine increases cardiac output and causes peripheral vasoconstriction, which may result in pulmonary edema. Cardiac Arrhythmias and Ischemia: Epinephrine may induce cardiac arrhythmias and myocardial ischemia in patients, especially patients suffering from coronary artery disease, or cardiomyopathy. Extravasation and Tissue Necrosis with Intravenous Infusion: Avoid extravasation of epinephrine into the tissues, to prevent local necrosis. When Adrenalin is administered intravenously, check the infusion site frequently for free flow. Blanching along the course of the infused vein, sometimes without obvious extravasation, may be attributed to vasa vasorum constriction with increased permeability of the vein wall, permitting some leakage. This also may progress on rare occasions to superficial slough. Hence, if blanching occurs, consider changing the infusion site at intervals to allow the effects of local vasoconstriction to subside. There is potential for gangrene in a lower extremity when infusions of catecholamine are given in an ankle vein. Antidote for Extravasation Ischemia: To prevent sloughing and necrosis in areas in which extravasation has taken place, infiltrate the area with 10 mL to 15 mL of saline solution containing from 5 mg to 10 mg of phentolamine, an adrenergic blocking agent. Use a syringe with a fine hypodermic needle, with the solution being infiltrated liberally throughout the area, which is easily identified by its cold, hard, and pallid appearance. Sympathetic blockade with phentolamine causes immediate and conspicuous local hyperemic changes if the area is infiltrated within 12 hours. Renal Impairment: Epinephrine constricts renal blood vessels, which may result in oliguria or renal impairment. ADVERSE REACTIONS: Most common adverse reactions to systemically administered epinephrine are headache; anxiety; apprehensiveness; restlessness; tremor; weakness; dizziness; sweating; palpitations; pallor; peripheral coldness; nausea/vomiting; and/or respiratory difficulties. Arrhythmias, including fatal ventricular fibrillation, rapid rises in blood pressure producing cerebral hemorrhage, and angina have occurred. DRUG INTERACTIONS: Drugs that counter the pressor effects of epinephrine include alpha blockers, vasodilators such as nitrates, diuretics, antihypertensives, and ergot alkaloids. Drugs that potentiate the effects of epinephrine include sympathomimetics, beta blockers, tricyclic antidepressants, MAO inhibitors, catechol-O-methyltransferase (COMT) inhibitors, clonidine, doxapram, oxytocin, levothyroxine sodium, and certain antihistamines. Drugs that increase the arrhythmogenic potential of epinephrine include beta blockers, cyclopropane and halogenated hydrocarbon anesthetics, antihistamines, exogenous thyroid hormones, diuretics, cardiac glycosides, and quinidine. Observe for development of cardiac arrhythmias. Potassium-depleting drugs, including corticosteroids, diuretics, and theophylline, potentiate the hypokalemic effects of epinephrine. USE IN SPECIFIC POPULATIONS: Elderly patients and pregnant women may be at greater risk of developing adverse reactions when epinephrine is administered parenterally. INDICATION AND USAGE Hypotension associated with Septic Shock Adrenalin is indicated to increase mean arterial blood pressure in adult patients with hypotension associated with septic shock. Click for Full Prescribing Information. About Endo Endo is a diversified specialty pharmaceutical company boldly transforming insights into life-enhancing therapies. Our passionate team members collaborate to develop and deliver these essential medicines. Together, we are committed to helping everyone we serve live their best life. Learn more at or connect with us on LinkedIn. Cautionary Note Regarding Forward-Looking Statements This press release contains forward-looking statements including, but not limited to, the statements by Mr. Sims and any statements relating to product launch, quality, efficacy, improved treatment, workflow efficiencies, reduced risks, waste or costs, and any statements that refer to expected, estimated or anticipated future results or that do not relate solely to historical facts. Statements including words such as "believes," "expects," "anticipates," "intends," "estimates," "plan," "will," "may," "look forward," "intends," "guidance," "future," "potential" or similar expressions are forward-looking statements. Because these statements reflect Endo's current views, expectations and beliefs concerning future events, they involve risks and uncertainties, some of which Endo may not currently be able to predict. Although Endo believes that these forward-looking statements and other information are based upon reasonable assumptions and expectations, readers should not place undue reliance on these or any other forward-looking statements and information. Actual results may differ materially and adversely from current expectations based on a number of factors, including, among other things, regulatory compliance, unexpected litigation or disputes, Endo's ability to successfully implement and execute on its strategies and initiatives, and changes in competitive, market or regulatory conditions. Endo assumes no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise, except as may be required under applicable securities laws. Additional information concerning risk factors, including those referenced above, can be found in Endo's press releases and in its public filings with the U.S. Securities and Exchange Commission, including the discussion under the heading "Risk Factors" in Endo's most recent Form 10-Q and in Endo's final prospectus filed pursuant to Rule 424(b) under the Securities Act of 1933, as amended, in connection with Endo's Form S-1/A. SOURCE Endo, Inc. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

SOUTHFIELD, Mich., July 18, 2024 /PRNewswire/ -- MASSIVE: Medical and Subrogation Specialists have been selected by the Personal Injury Trustee and Claims Administrator to be the exclusive Lien Resolution Administrator for the Endo Opioid Bankruptcy Trust. MASSIVE has a wide range of experience working on Mass Tort projects and was also selected as the exclusive lien resolution administrator in the Just for Men hair dye, Mallinckrodt Opioid Bankruptcy Trust, Purdue Opioid Bankruptcy Trust, Cordis IVC filter, and as the Flint Water case co-lien resolution administrator. Continue Reading "MASSIVE is excited to, once again, help those harmed by the Opioid crisis." Ryan Weiner, Esq., Partner at MASSIVE Post this "MASSIVE is excited to, once again, help those harmed by the Opioid crisis," says Ryan Weiner, Esq., Partner at MASSIVE. "We will work with enthusiasm and diligence to reduce lien holders' claims against each claimant's settlement award." In early 2024, Endo Health Solutions Inc. agreed to resolve both criminal and civil investigations for their role in the opioid epidemic. MASSIVE expects to resolve liens for more than 30,000 injured claimants. We are eager to help these victims maintain their settlement dollars. ABOUT MASSIVE MASSIVE: Medical and Subrogation Specialists is a nationwide provider of healthcare lien resolution services. By working hand in hand with personal injury law firms across the nation in both Single Event and Mass Tort cases, MASSIVE expedites settlements through cutting-edge software, services, and support. SOURCE MASSIVE: Medical and Subrogation Specialists

根据药明康德内容部统计，截至2024年5月31日，今年5月全球生物医药领域共计完成超过160起融资活动。其中，有17家致力于开发创新药的公司的单笔融资额突破了5000万美元大关，累计公开披露的融资总额已经超过了20亿美元。值得一提的是，在这些大额融资案例中，共有9家公司募集的资金超过了1亿美元。这些公司不仅涵盖了传统的小分子药物研发，也包括了抗体偶联药物（ADC），双特异性抗体等新分子疗法领域。在接下来的内容中，我们将依据公开资料为读者详细介绍其中5家早期融资超过1亿美元的创新药开发公司，探讨它们所开发的创新疗法以及这些疗法未来可能带来的患者福祉。 5月21日，AltruBio宣布成功完成超额认购的B轮融资，筹集资金高达2.25亿美元。获得资金将用于推进该公司潜在“first-in-class”免疫检查点增强剂（ICE）ALTB-268的临床开发。目前ALTB-268正在一项2a期临床试验中用于治疗生物制品难治性溃疡性结肠炎（UC）患者。 ALTB-268是一种四价PSGL-1激动性抗体，PSGL-1是一种免疫检查点蛋白，它的激活会下调T细胞的活性。ALTB-268是一款能够优先下调长期激活T细胞的ICE，通过抑制T细胞效应功能，恢复免疫系统的稳态，从而从源头上治疗免疫疾病。此外，它不会下调初始T细胞和急性激活T细胞的活性，因此不会导致全身性的免疫抑制。 ALTB-268为皮下注射剂型，方便患者使用。1期临床研究已证明其在健康志愿者中的安全性和耐受性，所有队列中均未出现严重不良事件。该公司计划于2024年晚些时候启动一项在UC患者中进行的随机2b期研究。鉴于T细胞调节在多种免疫疾病中的重要性，ALTB-268在其他适应症中的扩展潜力巨大。 周慧泉博士是AultruBio公司总裁兼首席执行官。她在药物开发和生物医药领域具有超过20年的经验。周博士曾是德国拜耳公司全球生物科技运营总裁。加入拜耳之前，是美国辉瑞公司的医药运营副总裁，领导生物制品和小分子产品的开发和制造。在周博士的职业生涯中，她曾先后任职于基因泰克、辉瑞、艾伯维和雅培公司，为多项创新产品完成生物制品许可申请（BLAs），新药申请（NDAs）和IND申请。 5月21日，Pheon Therapeutics宣布完成1.2亿美元B轮融资，融资所获得款项将用于开发其三款差异化、潜在“first-in-class”抗体偶联药物。其中一款ADC疗法预计在今年进入1期临床试验。 这三款ADC所靶向的是一种未公开的新靶点，该靶点在多种实体肿瘤中高度表达。其中一款ADC疗法使用拓扑异构酶-1抑制剂作为有效载荷，药物抗体比（DAR）达8，在临床前研究中展现极佳的治疗指数。另外两款ADC则利用其他连接子与有效载荷技术，进一步探索该靶点的治疗潜力。该公司预计将于2024年开始其首个1期临床试验，并迅速将试验推进至剂量扩展队列。这笔资金还将用于扩展Pheon的内部技术平台套件，以进一步优化其旗下ADC的构成。 Cyrus Mozayeni博士担任Pheon的首席执行官。他在生物技术行业拥有超过20年的经验，并在推动战略业务增长方面有着卓越的成就。他曾担任Atlas Venture的驻场创业家（Entrepreneur-in-Residence），并在此期间创立了Vedere Bio和Vedere Bio II。他从公司成立初期就担任两家公司的首席执行官，直至诺华以2.8亿美元款项将其收购。在加入Atlas Venture之前，他是CODA Biotherapeutics和Oncorus公司的联合创始人，并曾担任总裁及首席商务官职务。在加入Oncorus之前，Mozayeni博士在bluebird bio担任副总裁及全球业务拓展和联盟管理部门的负责人。 5月15日，黑石（Blackstone）集团正式推出Uniquity Bio公司，这是一家专注于免疫学和炎症的临床阶段药物开发公司。该公司针对胸腺基质淋巴细胞生成素（TSLP）的单克隆抗体solrikitug的2期临床试验的IND申请已获得美国FDA许可，并从黑石集团获得高达3亿美元的资金支持，用于推进该药物在多个适应症中的研发。 Solrikitug是一种高效的抗TSLP单克隆抗体，能阻止TSLP与其受体的结合。鉴于TSLP在炎症级联反应顶端的主控调节因子地位，solrikitug在广泛的免疫学和炎症疾病中具有潜在的应用价值。Solrikitug最初由默沙东（MSD）公司开发，Uniquity Bio获得了这款抗体疗法的开发权益。该公司计划在下个月启动针对慢性阻塞性肺病（COPD）和哮喘的2期临床试验，并且将在多个具有高度未竟需求的呼吸道和胃肠道疾病中评估solrikitug的潜在“best-in-class”疗效。 Brian Lortie先生是Uniquity Bio的首席执行官。他是一位经验丰富的医药行业领导者。在加入Uniquity Bio之前，他曾担任Onspira Therapeutics的首席执行官，该公司是一家专注于罕见肺病的生物医药公司，在2019年被Altavant Sciences / Sumitomo Dainippon Pharma收购。他还曾担任Endo Pharmaceuticals医药业务的总裁，并在GSK进行了超过15年的商业和开发执行工作。 5月9日，Attovia Therapeutics宣布完成1.05亿美元的B轮融资，使该公司自2023年6月成立以来的总融资额达到1.65亿美元。所得资金将用于推进其核心项目ATTO-1310和ATTO-002的初期临床开发，扩展公司在免疫学和炎症领域的研发管线，并进一步开发ATTOBODY技术平台。 该公司的ATTOBODY平台通过专有的连接技术将两个与同一靶点蛋白两个不同表位结合的抗体片段连接起来，构成双互补位生物制品（biparatopic biologics）。其主打在研产品ATTO-1310是一种潜在“first-in-class”，长半衰期的抗IL31 ATTOBODY，ATTO-002则是一种双特异性抗IL31/IL13 ATTOBODY，两者均有望成为治疗各种免疫介导疾病的潜在“best-in-class”药物。ATTO-1310目前正在进行支持IND申请的临床前研究，计划在2024年底前进入临床阶段，用于治疗特应性皮炎和其他瘙痒性疾病。 Attovia公司官网表示，ATTOBODY具有多种优势，包括可与靶点以皮摩尔的亲和力结合，并且亲和力可以调节，从而获得优化的药代动力学特征。此外，它具有模块化结构，可以将不同ATTOBODY模块结合在一起构建多特异性生物制品。而且ATTOBODY可以和各种不同延长半衰期的片段融合，根据需要延长生物制品的半衰期，甚至具有每三个月给药一次的潜力。 本轮融资由Goldman Sachs Alternatives领投，新投资者包括Cormorant Asset Management、Nextech Ventures、Redmile Group、EcoR1 Capital、Marshall Wace和Logos Capital。公司的现有投资者Frazier Life Sciences、venBio和Illumina Ventures也参与了本轮融资。 傅涛先生是Attovia的创始人兼首席执行官，在医药行业拥有超过25年的业务拓展、综合管理、运营、战略和商务领导经验。他还担任Frazier Life Sciences的风险合伙人职务。在创立Attovia之前，傅先生曾在再鼎医药担任总裁兼首席运营官，随后成为首席战略官。 5月2日，Reunion Neuroscience公司宣布完成1.03亿美元A轮融资。获得资金将用于支持其在研疗法RE104的2期临床试验，用于治疗产后抑郁症（PPD），并扩展针对其它具有显著未满足需求的心理疾病的开发。本轮融资由MPM BioImpact和Novo Holdings领投，Arkin Bio Capital、Mitsui & Co. Global Investment、Plaisance Capital、FemHealth Ventures和Palo Santo参与投资。 Reunion Neuroscience公司的主打疗法RE104是一款潜在“best-in-class”的4-OH-DiPT前药，靶向血清素2A受体（5HT2AR）。RE104是一种致幻化合物，在1期临床试验中，它的致幻活性与裸盖菇素（psilocybin）相似，但持续时间只有3-4小时，并且表现出与裸盖菇素类似的安全性特征。 Reunion计划在本季度开始2期临床试验RECONNECT的患者注册。这项随机双盲，含活性对照的研究将评估RE104治疗中重度产后抑郁患者的疗效和安全性。 Greg Mayes先生是Reunion Neuroscience的总裁兼首席执行官。他在药物开发领域拥有20多年的经验。此前他担任Antios Therapeutics的总裁兼首席执行官。在加入Antios之前，Mayes先生创立了Engage Therapeutics，并担任该公司的总裁兼首席执行官。他带领Engage完成了首个用于迅速终止活跃性癫痫发作的药物-医疗器械组合的2b期有效性研究。该公司后来被优时比（UCB）收购。 参考资料：[1] 各公司官网 内容来源于网络，如有侵权，请联系删除。